$$\rightleftharpoonup{xx}$$
$$\longleftharp{xx}$$,
$$\longrightharp{xx}$$,
The peptide gel fabrication method described here allows the user to define and create a bespoke 3D culture environment. While the mechanical environment is determined primarily by peptide concentration, matrix components of interest may also be added at controlled densities, as shown by the example calculation in Figure 1. In its simplest form, however, the peptide gel protocol provides a method for encapsulating cells in a matrix-free 3D environment. Figure 2 shows how this approach may be combined with a wide range of cancer models, including fluorescently labeled cancer cell lines (Figure 2A) and patient-derived xenograft (PDX) material (Figure 2B,C). Importantly, cell lines and PDX material may both be cultured within the gels in serum-free conditions (Figure 2C,D), providing a 3D culture system with fully defined composition.
Since the peptide itself does not contain any cell-binding motifs, encapsulated cells typically display a rounded morphology in the unmodified peptide gels. Figure 3A demonstrates this for human mammary fibroblasts in a 6 mg/mL peptide gel, compared with their classic elongate morphology seen in pure Matrigel and a pure collagen gel. Importantly however, the peptide gel protocol allows incorporation of matrix components of interest. Figure 3A demonstrates how addition of 200 μg/mL collagen I can restore the elongate fibroblast morphology in the peptide gels.
Matrix additions can also support the growth and organization of other cell types, for instance MCF10A, as shown in Figure 3B. In this case, addition of 100 μg/mL collagen I to a 6 mg/mL peptide gel allows acinar structures to form by day 7. Further complexity may also be introduced by incorporation of a supportive cell layer in indirect co-culture. Figure 3C demonstrates how the combined approach of matrix incorporation and indirect co-culture with human mammary fibroblasts can enhance MCF10A growth and organization.
Another important parameter is the concentration of peptide used in peptide gel fabrication. Figure 4A shows an example of how controlling peptide concentration, in this case between 4 and 10 mg/mL, results in a stiffness ranging between 100s to 1000s of Pa. These gels may be fabricated matrix free or can be created with matrix additions to allow simultaneous control of both stiffness and composition. Peptide gels with matrix additions may be sectioned and stained to allow the distribution of these additions to be visualized. Figure 4B, C show two approaches for doing this: embedding in 4% agar followed by standard tissue processing and paraffin embedding for immunohistochemistry (Figure 4B) or embedding in 2% agar followed by vibratome sectioning and fluorescent staining (Figure 4C).
When modifying the composition of the peptide gels, it is crucial to ensure that these changes do not impact the mechanical environment initially presented to the cells. Figure 4D demonstrates how modifications to the peptide concentration can be used to offset any changes to the peptide gel stiffness on matrix incorporation. Bulk oscillatory rheology measurements of gel stiffness (storage modulus, G’) can then distinguish between the effects of gel composition and stiffness on cell morphology. As shown in the bright field images, MDA MB 231 cells develop an elongate morphology on collagen addition to either 10 mg/mL or 15 mg/mL peptide gels. Figure 4E shows that these elongated cells stain positive for pFAK, indicating an interaction with their surrounding matrix. The initially matrix-free environment of the peptide gels also makes them an ideal platform for studying cellular synthesis and deposition of matrix components of interest. Figure 4F shows the localized deposition of collagen I by MCF7 cells encapsulated in 10 mg/mL peptide gels.
One of the key advantages of the peptide gels is the ease with which standard laboratory methods can be applied to their analysis. Material can be extracted for qRT-PCR to determine gene expression profiles (as shown in our recent publication5). Imaging by bright-field microscopy additionally allows real-time visualization of cell growth. Figure 5 shows some of the typical troubleshooting issues that may be encountered in unsuccessful peptide gels: incomplete mixing of the gel precursor (Figure 5A,B); incorrect optimization of peptide concentration (Figure 5C,D) or seeding density (Figure 5E,F); and incorrect neutralization of acidic collagen prior to incorporation in the peptide gels (Figure 5G,H). Peptide concentration and seeding density, in particular, must be optimized for each cell line and peptide source, to ensure that the culture environment is appropriately defined, and representative of the application of interest.

Figure 1: An example calculation for matrix composition and seeding density. This example workflow describes the procedure that would be followed to seed two peptide gel precursors with additions of 100 µg/mL collagen, at a final cell density of 1 x 105 cells/mL. Please click here to view a larger version of this figure.

Figure 2: Matrix-free peptide gels provide a suitable 3D culture platform for cell line and patient-derived cancer models. (A) HCT116 colorectal cancer and MCF7 breast cancer cell lines, constitutively expressing the fluorescent markers mCherry and tdTomato respectively, form cell clusters in 6 mg/mL gels by day 9 (left), and may be imaged live using fluorescent microscopy (right, scale bar 50 µm); (B) Patient-derived xenograft (PDX) cells from a triple negative breast cancer patient (BR8) form cell clusters by day 7 in 10 mg/mL peptide gels; (C) PDX cells from estrogen receptor positive breast tumours (BB3RC31) may be grown in serum-free conditions18, shown with basement membrane matrix (e.g. Matrigel) control at matched passage for comparison; (D) MCF7 breast cancer cells are viable in 6 mg/mL peptide gels in matrix-free and serum-free conditions, as assessed using a LIVE/DEAD cell assay at day 7. KSR = knockout serum replacement, MS medium = mammosphere medium19. Scale bar 100 µm unless specified. Please click here to view a larger version of this figure.

Figure 3: Peptide gel complexity may be increased by introduction of matrix additions and co-culture. (A) Human mammary fibroblast cell line HMFU19 requires collagen additions to restore an elongate morphology in a 6 mg/mL peptide gel, shown with pure basement membrane matrix (e.g. Matrigel) and 1.5 mg/mL rat tail collagen I gel for comparison, scale bar 50 µm; (B) MCF10A normal breast cells form acinar structures by day 7 in 6 mg/mL peptide gels on addition of 100 µg/mL human collagen I, scale bar 100 µm; (C) Combined addition of matrix components fibronectin/HA (hyaluronic acid, molecular weight 804 kDa) and HMFU19 in indirect co-culture increase the size and organization of MCF10A acini in 10 mg/mL peptide gels as assessed by cleaved caspase 3 staining, scale bar 50 µm. Please click here to view a larger version of this figure.

Figure 4: Peptide gels allow independent control of stiffness and composition, and assessment of cell-deposited matrix. (A) Bulk rheology measurements demonstrating a typical stiffness range (storage modulus, G’) achievable by control of peptide concentration, * indicates p < 0.05; (B) Immunohistochemistry showing staining of 150 µg/mL collagen I in a 10 mg/mL peptide gel with encapsulated MCF7 (day 7, scale bar 100 µm); (C) Immunofluorescence of collagen I distribution in a 6 mg/mL peptide gel with 200 µg/mL human collagen I, by agar embedding and vibratome sectioning, scale bar 25 µm; (D) Addition of 200 µg/mL collagen I gives a modest decrease in the storage modulus, G’, of 10 mg/mL peptide gels (bulk oscillatory rheology), offset by increasing peptide concentration to 15 mg/mL. MDA MB 231 triple negative breast cancer cells are shown in each condition (day 7, scale bar 50 µm); (E) MDA MB 231 in 15 mg/mL peptide gels with 200 µg/mL human collagen I show elongation and interaction with the matrix via pFAK staining (day 14, scale bar 50 µm); (F) In situ staining of MCF7 collagen I deposition in an initially matrix-free 10 mg/mL peptide gel (day 10, scale bar 100 µm). Please click here to view a larger version of this figure.

Figure 5: Common peptide gel troubleshooting issues may be resolved using bright-field microscopy. Cells shown are MCF10A normal breast epithelial cells, at day 7 unless specified. (A) A correctly mixed gel precursor should be optically clear with no inconsistencies, whereas (B) insufficient mixing/neutralization can cause visible inhomogeneities/streaks in the peptide gel (white arrows); (C) MCF10A form acinar structures in 6 mg/mL peptide gels on addition of HMFU19 indirect co-culture, however (D) at 15 mg/mL the peptide concentration is too high to allow acinar formation; (E) MCF10A seeded at 5 x 105 cells/mL form acinar structures in 6 mg/mL gels on addition of 100 μg/mL collagen I, however (F) at 2 x 105 cells/mL cell density is too low to allow acinar formation; (G) Collagen additions can produce large cell clusters by day 14, however (H) incorrect addition (collagen neutralization too early in the process) can prevent cluster growth. Scale bar 100 µm. Please click here to view a larger version of this figure.